| CPC A61K 35/747 (2013.01) [A23L 33/105 (2016.08); A23L 33/135 (2016.08); A23L 33/15 (2016.08); A61K 31/525 (2013.01); A61K 35/742 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01)] | 18 Claims |

|
1. A pharmaceutical composition comprising
a) a combination of four heterologous microbes comprising:
Lactobacillus harbinensis, Lactobacillus brevis, Lactococcus lactis, and Bacillus velezensis, wherein the heterologous microbes are formulated as a synthetic microbial consortium comprising about 1.0×108 to about 1.0×1012 CFU of each of the heterologous microbes, wherein at least one of the heterologous microbes comprises a 16S rRNA sequence having at least 97% identity to any one of SEQ ID NOs: 43, 198, 221, and 224, formulated in an amount effective to produce an anti-inflammatory effect in a human subject; and
b) a pharmaceutically acceptable excipient.
|